RecruitingAngelman Syndrome
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
Eligible age
0–50 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.
Sponsor: Ionis Pharmaceuticals, Inc.
Where it's recruiting
California
San Diego
Colorado
Aurora
Illinois
Chicago
Massachusetts
Boston
North Carolina
Carrboro
Texas
Houston
Source: ClinicalTrials.gov · NCT05127226 · last updated 2025-11-14